Sumitomo Pharma Email Format

Pharmaceutical Manufacturing
1,001-2,500 employees
Marlborough, MA, USA

Sumitomo Pharma America is a biopharmaceutical company focused on delivering therapeutic breakthroughs in oncology, urology, rare disease, cell and gene therapies, and CNS.

Find contacts at Sumitomo Pharma

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@us.sumitomo-pharma.com

Company Overview

Industry
Pharmaceutical Manufacturing
Headquarters
Marlborough, MA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Subsidiary
Key Executives
Toru Kimura (Representative Director, President and CEO), Motoyuki Sakai (Representative Director, Executive Vice President (Global Finance Administration)), Andrew Hetherington (Chief Technology & Quality Officer)

Tech Stack

Snowflake

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Sumitomo Pharma?

Sumitomo Pharma uses the first.last format, so Jane Smith would be jane.smith@us.sumitomo-pharma.com.

What therapeutic areas does Sumitomo Pharma America focus on?

Sumitomo Pharma America focuses on oncology, CNS, women's health, urology, rare disease, and cell and gene therapies, with an emphasis on areas of high unmet medical need.

Which approved products does Sumitomo Pharma America currently market in the US?

Sumitomo Pharma America markets several approved products in the US, including ORGOVYX for prostate cancer, MYFEMBREE for women's health, GEMTESA for overactive bladder, RETHYMIC for rare disease, LATUDA for CNS conditions, and APTIOM for epilepsy.

Who leads Sumitomo Pharma America as President and CEO in 2026?

Tsutomu Nakagawa, Ph.D. serves as President and CEO of Sumitomo Pharma America in 2026, while Toru Kimura leads the parent company, Sumitomo Pharma Co., Ltd., as Representative Director, President and CEO.

How was Sumitomo Pharma America formed, and how can I find a specific contact there?

Sumitomo Pharma America was formed through the consolidation of seven US affiliate companies, including Sunovion Pharmaceuticals and Myovant Sciences. Tools like Clay can help you find and verify specific contacts at Sumitomo Pharma America for outreach or prospecting.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles